Inhibitor Therapeutics, Inc. (INTI)

OTCMKTS · Delayed Price · Currency is USD
0.1110
-0.0120 (-9.76%)
Mar 4, 2026, 9:30 AM EST
Market Cap17.43M -22.1%
Revenue (ttm)n/a
Net Income-3.43M
EPS-0.02
Shares Out172.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,000
Average Volume42,910
Open0.1110
Previous Close0.1230
Day's Range0.1110 - 0.1110
52-Week Range0.0338 - 0.1230
Beta-0.36
RSI57.81
Earnings DateMar 27, 2026

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 9
Stock Exchange OTCMKTS
Ticker Symbol INTI
Full Company Profile

Financial Performance

Financial Statements